Spots Global Cancer Trial Database for recombinant human adenovirus type 5
Every month we try and update this database with for recombinant human adenovirus type 5 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT06253598 | Hepatocellular ... | Recombinant Hum... Lenvatinib Tislelizumab | 18 Years - 75 Years | First Affiliated Hospital Bengbu Medical College | |
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | NCT05664139 | Malignant Melan... Liver Metastase... | Recombinant Hum... | 18 Years - 75 Years | Fujian Cancer Hospital | |
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | NCT05124002 | Cholangiocarcin... | Recombinant Hum... HAIC of FOLFOX | 18 Years - | Beijing Tsinghua Chang Gung Hospital | |
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | NCT05664139 | Malignant Melan... Liver Metastase... | Recombinant Hum... | 18 Years - 75 Years | Fujian Cancer Hospital | |
Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | NCT05664139 | Malignant Melan... Liver Metastase... | Recombinant Hum... | 18 Years - 75 Years | Fujian Cancer Hospital |